The cost of opioid-related adverse drug events

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 28, Issue 3, 2014, Pages 282-293

  Kane Gill, Sandra L ^a,b,c   Rubin, Ellen C ^a   Smithburger, Pamela L ^a,c   Buckley, Mitchell S ^d   Dasta, Joseph F ^e,f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d Department of Pharmacy Banner Good Samaritan Medical Center   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Adverse drug events; Costs and cost analysis; Drug related side effects and adverse reactions; Economic burden; Opioid analgesics; Opioid related adverse drug events

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT;

ADVERSE DRUG REACTION; ARTICLE; CONFUSION; CONSTIPATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; INTESTINE OBSTRUCTION; NAUSEA AND VOMITING; OUTPATIENT; POSTOPERATIVE ILEUS; PRURITUS; RESPIRATION DEPRESSION; URINE RETENTION; CHEMICALLY INDUCED; COST OF ILLNESS; ECONOMICS; NAUSEA; VOMITING;

ANALGESICS, OPIOID; CONSTIPATION; COST OF ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NAUSEA; VOMITING;

EID: 84906814927     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2014.938889     Document Type: Article

References (43)

1. Thomas EJ, Studdert DM, Newhouse JP, et al. Costs ofmedical injuries in Utah and Colorado. Inquiry. 1999:36:255-264.
2. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29-34.
3. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997;277:307-311.
4. Kane-Gill SL, Jacobi J, Rothschild JR. Adverse drug events in the ICU: risk factors, impact and role of team care. Crit Care Med. 2010;38(6 Suppl):s83-s89
5. Institute of Medicine, Committee on Identifying and Preventing Medication Errors, PreventingMedication Errors.Washington, DC: National Academies Press; 2007:124-125.
6. Ford D, Luttrell N. Leadership in patient safety: IV pump autoprogramming. Paper presented at Cerner Health Conference; October 2009; Kansas City, MO.
7. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315-1321.
8. Von KorffM, Kolodny A, Deyo RA, Chou R. Long-term opioid therapy reconsidered. Ann Intern Med. 2011;155:325-328.
9. Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25:276-283.
10. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomized trials of oral opioids. Arthritis Res Ther. 2005;7:R1046-R1051.
11. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in the management of chronic non-cancer pain: systematic review of safety and efficacy. Pain. 2004;112:372-380.
12. Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol and opioids. Anesthesiol Clin. 2011;29:567-585.
13. Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001;21:129-143.
14. Lehmann KA, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: An economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur J Health Econ. 2002;3:111-119.
15. Duggan AK. The cost of constipation in morphine patients and the economic possibilities with tramadol. Br J Med Econ. 1995;9:21-29.
16. Hass B, Lungershausen J, Hertel N, et al. Cost-effectiveness of strong opioids focusing on the long-term effects of opioidrelated fractures: A model approach. Eur J Health Econ. 2009;10:309-321.
17. Frei A, Andersen S, Hole P, Jensen NH. A one year health economic model comparing transdermal fentanyl with sustainedrelease morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother. 2003;17:5-26.
18. Morgan Friedman. The inflation calculator. Available at: http://www.westegg.com/inflation/infl.cgi. Accessed May 22, 1014.
19. Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioidrelated adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33:383-391.
20. Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41:400-407.
21. Classen DC, Pestonik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301-306.
22. Oderda G, Gan T-J, Johnson BH, Robinson SB. Effect of opioid relate advese events on outcomes in selected surgical patients. J Pain Palliat Care Pharmacother. 2013;27:62-70.
23. Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S. The prevalence of economic impact of prescription opioid-related side effects among patients with chronic noncancer pain. J Opioid Manag. 2013;9:239-254.
24. Dunlop W, Uhl R, Khan I, Taylor A, Barton G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioidinduced constipation: A UK cost-utility analysis. J Med Econ. 2012;15:564-575.
25. Takemoto ML, Fernandes RA, Almeida GR, Monteiro RD, Colomvini-Neto M, Bertola-Neto A. Health care resource use and costs in opioid-treated patients with and without constipation in Brazil. Value Health. 2011;14(5 Suppl 1):S78-S81.
26. Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage. 2010;40:696-703.
27. Wee B, Adams A, Thompson K, Percival F, Burslem K, Jobanputra M. How much does it cost a specialist palliative care unit to manage constipation in patients receiving opioid therapy? J Pain Symptom Manage. 2010;39:644-654.
28. Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Managed Care. 2010;19:44-51.
29. KwongWJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010;44:630-640.
30. Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009;23:231-241.
31. Flynn TN, Guest JF. Cost of managing constipation among terminally ill cancer patients treated with transdermal fentanyl and 12 hour sustained-release morphine in Canada. J Med Econ. 1999;2:15-32.
32. Carroll NV, Miederhoff PA, Cox FM, Hirsch JD. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J Clin Anesth. 1994;6:364-369.
33. Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology. 2000;92:958-967.
34. Suh DC, Kim MS, Chow W, Jang EJ. Use of medications and resources for treatment of nausea, vomiting, or constipation in hospitalized patients treated with analgesics. Clin J Pain. 2011;27:508-517.
35. Asgeirsson T, El-Badawi KI, Mahmood A, Barletta J, Luchtefeld M, Senagore AJ. Postoperative ileus: it costs more than you expect. J Am Coll Surg. 2010;210:228-231.
36. Iyer S, Saunders WB, Stemkowski S. Economic burden of postoperative ileus associated with colectomy in the United States. J Managed Care Pharm. 2009;15:485-494.
37. Anastassopoulos KP, Chow W, Tapia CI, et al. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Managed Care Pharm. 2012t;18:615-626.
38. Swegle JM, Logemann C. Management of common opioidassociated adverse effects. Ann Fam Physician. 2006;74: 1347-1354.
39. Voepel-Lewis T, Wagner D, Burke C, et al. Early adjuvant use of nonopioids associated with reduced odds of serious postoperative opioid adverse events and need for rescue in children. Paediatr Anaesth. 2013;23:162-169.
40. Webster L. Efficacy and safety of dual-opioid therapy in acute pain. Pain Med. 2012;13(Suppl 1):s12-s20.
41. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263-306.
42. Centers for Medicare and Medicaid Services. Hospital consumer assessment of healthcare providers and systems. Available at: http://www.hcahpsonline.org/ home.aspx. Accessed May 22, 2014.
43. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain. 2003;4:234-256.